Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged formulation
Sandoz lost two IPRs challenging Humira® patents - what does this mean for other biosimilars?

Sandoz was denied institution on two IPRs against Humira® patents owned by AbbVie.  As we previously discussed, in late 2017, Sandoz filed eight different IPRs against Humira® patents.  Two of those IPRs just failed to reach institution.  What are the take-aways, for Sandoz and any other Humira® biosimilars?

Read More
Markman AdvisorsAbbVie, Humira, Sandoz, Amgen, Coherus Biosciences, Coherus, IPR, Inter Partes Review, PTAB, patent, formulation, psoriasis Comment